卡瑞利珠单抗联合培美曲塞、顺铂治疗一线化疗失败的晚期原发性肝癌患者的效果研究  

Study on the Effect of Carrelizumab Combined with Pemetrexed and Cisplatin in the Treatment of Advanced Liver Cancer with First-line Chemotherapy Failure

作　　者：于小盼 王清溪 赵旭林[2] YU Xiaopan;WANG Qingxi;ZHAO Xulin(The Second Department of Internal Medicine,Nanyang No.1 People’s Hospital Western District,Nanyang 473000,Henan,China;The First Department of Oncology,Nanyang No.1 People’s Hospital,Nanyang 473000,Henan,China)

机构地区：[1]南阳市第一人民医院西区医院内二科,河南南阳473000 [2]南阳市第一人民医院肿瘤内一科,河南南阳473000

出　　处：《中国药物滥用防治杂志》2024年第1期122-126,共5页Chinese Journal of Drug Abuse Prevention and Treatment

摘　　要：目的:探讨卡瑞利珠单抗联合培美曲塞、顺铂在一线化疗失败的晚期原发性肝癌中的作用。方法:选取医院2019年1月—2021年5月收治的118例一线化疗失败的晚期原发性肝癌患者,采用随机数字表分为对照组和观察组,各59例。对照组采用培美曲塞、顺铂治疗,观察组联合卡瑞利珠单抗治疗。比较两组抗癌效果、程序性死亡受体-1(PD-1)表达、血清甲胎蛋白(AFP)、血管内皮生长因子(VEGF)水平、不良反应发生率及生存率。结果:观察组临床获益率、总有效率均高于对照组(P<0.05);观察组PD-1、AFP和VEGF水平低于对照组(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05);观察组随访1年内生存率高于对照组(P<0.05)。结论:对一线化疗失败的晚期原发性肝癌采用卡瑞利珠单抗可提高疗效,降低PD-1表达和肿瘤标志物水平,安全性高且可提高生存率。Objective:To explore the role of carlizumab combined with pemetrexed and cisplatin in advanced liver cancer with firstline chemotherapy failure.Methods:A total of 118 patients with advanced primary liver cancer who failed first-line chemotherapy in our hospital from January 2019 to May 2021 were selected and randomly divided into control group and observation group,with 59 cases in each group.The control group was treated with pemetrexed and cisplatin,and the observation group was treated with carrelizumab.The anti-cancer effect,programmed death receptor-1(PD-1)expression,serum alpha-fetoprotein(AFP),vascular endothelial growth factor(VEGF)levels,incidence of adverse reactions and survival rate were compared between the two groups.Results:The clinical benefit rate and total effective rate of the observation group were higher than those of the control group(P<0.05).After treatment,the levels of PD-1,serum AFP,VEGF in the observation group were lower than those in the control group(P<0.05).There were no significant differences in adverse reactions between the two groups(P>0.05).The survival rate of the observation group was higher than that of the control group within 1 year(P<0.05).Conclusion:Carelizumab can improve the therapeutic effect of advanced liver cancer who failed to receive first-line chemotherapy,reduce the expression of PD-1 and the levels of tumor markers,which is safe and can improve the survival rate.

关 键 词：卡瑞利珠单抗 肝癌 肿瘤标志物 

分 类 号：R735.7[医药卫生—肿瘤]